ArticleBMC gastroenterology2025
The association between serum HbA1c and infected pancreatic necrosis in acute necrotizing pancreatitis.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundGiven the evidence that poor glycemic control is associated with immunological dysfunction, serum glycosylated hemoglobin A1c (HbA1c), as a useful indicator reflecting blood glucose homeostasis, has potential to predict infectious complications. In this study, we aimed to explore the association between poor glycemic control (HbA1c ≥ 6.5 as an indicator) and infected pancreatic necrosis (IPN) in patients with acute necrotizing pancreatitis (ANP).
methodsThis is a secondary analysis of pooled data from the TRACE trial and a retrospective single-center cohort, involving ANP patients admitted within 72 h after onset of abdominal pain between March 2017 and October 2022. Patients had no HbA1c data at enrollment/admission were excluded. The Multivariable Cox proportional hazards regression (MCPHR) model was used to assess the association between poor glycemic control and 90-day IPN. Mediation analyses were used to define the relationships between the independent variables and 90-day IPN.
resultsA total of 153 patients were enrolled, of whom 20.3% (31/153) patients developed IPN within 90 days. Most patients with IPN had HbA1c ≥ 6.5% at admission (25/31, 80.6%), compared to 38.5% (47/122) in the non-IPN patients. In the MCPHR model, HbA1c ≥ 6.5% [HR (95%CI) = 4.10 (1.42-11.90); p = 0.009], SOFA score on admission [HR (95%CI) = 1.47 (1.26-1.70); p < 0.001] and pancreatic necrosis extent > 50% [HR (95%CI) = 3.15 (1.06-9.35); p = 0.039] were independent risk factors for 90-day IPN. In addition, patients with HbA1c ≥ 6.5% experienced a higher incidence of hyperglycemia during the first week of enrollment [RR (95%CI) = 9.19 (4.23-19.95); p < 0.001]. Mediation analyses showed that the presence of hyperglycemia completely mediated the association between HbA1c ≥ 6.5% and 90-day IPN.
conclusionAmong ANP patients, HbA1c ≥ 6.5% was associated with the development of IPN. The mediation effect of hyperglycemia may explain it.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.